BIO-COURIER

What this means for you

Registered since 25 Jun 2024. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

97187427

Registration number

7430532

Mark type

Stylized text

Filed

23 Dec 2021

Registered

25 Jun 2024

Attorney of record

Evi Christou

Goods and services

• Class 001 — Chemicals: Nanoparticle substances and nanoparticles for use in industry, science and research; Silicon, namely, silicon for use in industry, science and research in the nature of biochemical catalysts; Silicon, namely, silicon nanoparticle materials for use in industry, science and research; Silicon, namely, porous silicon nanoparticle materials for use in industry, science and research; lipid nanoparticles for use in industry, science and research; Silicon, namely, silicon-lipid nanoparticles for use in industry, science and research; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for use in industry, science and research; Silicon, namely, silicon-stabilised lipid nanoparticles for use in industry, science and research; stabilised lipid nanoparticles for use in industry, science and research; materials being silicon for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacturing of pharmaceuticals; materials being silicon for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in gene therapy; materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; Silicon, namely, silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; materials for stabilising of chemical, biochemical and biological substances; nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, porous silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances; lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon-lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for stabilising of chemical, biochemical and biological substances; Silicon, namely, silicon-stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances; stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances; materials for stabilising nucleic acids; nanoparticle materials for stabilising nucleic acids; Silicon, namely, silicon nanoparticle materials for stabilising nucleic acids; Silicon, namely, porous silicon nanoparticle materials for stabilising nucleic acids; lipid nanoparticle materials for stabilising nucleic acids; Silicon, namely, silicon-lipid nanoparticle materials for stabilising nucleic acids; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids; Silicon, namely, silicon-stabilised lipid nanoparticles for stabilising nucleic acids; stabilised lipid nanoparticles for stabilising nucleic acids; materials for stabilising nucleic acid-lipid complexes; nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, porous silicon nanoparticle materials for stabilising of nucleic acid-lipid complexes; lipid nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon-lipid nanoparticle materials for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes; Silicon, namely, silicon-stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes; all of the foregoing other than for medical or veterinary purposes and excluding use in the agricultural industry
• Class 005 — Pharmaceuticals: Nanoparticle substances and nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; silicon nanoparticle substances and silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; porous silicon nanoparticle substances and porous silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical purposes; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and nanoparticle substances and nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; silicon nanoparticle substances and silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; porous silicon nanoparticle substances and porous silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments; nanoparticle substances and nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; silicon nanoparticle substances and silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; porous silicon nanoparticle substances and porous silicon nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; silicon-lipid nanoparticle substances and lipid nanoparticle preparations, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines for medical, veterinary and pharmaceutical treatment purposes; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for stabilising nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle materials for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle materials for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for controlled release and transfection of nucleic acids, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; all of the foregoing excluding use in the agricultural industry

Owner

• SISAF Ltd, GUILDFORD, Surrey, GB
• SISAF Ltd, GUILDFORD, Surrey, GB

Prosecution history

• 25 Jun 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
• 25 Jun 2024 — REGISTERED-SUPPLEMENTAL REGISTER
• 22 May 2024 — APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
• 11 Apr 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 11 Apr 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 11 Apr 2024 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
• 15 Jan 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 15 Jan 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 16 Oct 2023 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 16 Oct 2023 — FINAL REFUSAL E-MAILED
• 16 Oct 2023 — FINAL REFUSAL WRITTEN
• 05 Sept 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 05 Sept 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 05 Sept 2023 — ASSIGNED TO LIE
• 20 Apr 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED